The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

Jennifer Litton, MD, associate professor in the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses the impact of PARP inhibitors in breast cancer.

Funda Meric-Bernstam, MD, chair, Department of Investigational Cancer Therapeutics, medical director, Institute for Personalized Cancer Therapy, professor of medicine, The University of Texas MD Anderson Cancer Center, discusses the combination of CB-839 plus cabozantinib in patients with renal cell carcinoma.

Naval G. Daver, MD, stresses the importance of minimal residual disease testing, and highlights where research in the field is heading in order to achieve a higher cure rate in acute myeloid leukemia.

William G. Wierda, MD, PhD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses treatment options for patients with relapsed/refractory chronic lymphocytic leukemia.

Matthew H.G. Katz, MD, FACS, associate professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses preoperative chemoradiation for the treatment of patients with localized pancreatic cancer.

Jorge E. Cortes, MD, deputy chair of the Department of Leukemia in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses the data from the QuANTUM-R trial presented at the 2018 ASH Annual Meeting in relapsed/refractory acute myeloid leukemia (AML).

Douglas A. Nelson, MD, discusses key advances made in the treatment of patients with colorectal cancer and pancreatic cancer, and sheds light on remaining challenges in these paradigms.

Michael Wang, MD, a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the promise of venetoclax in the treatment of patients with relapsed/refractory mantle cell lymphoma.

Matthew H.G. Katz, MD, FACS, highlights pivotal trials in pancreatic cancer and how these data are shifting the treatment paradigm for these patients.

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the ReDOS study in patients with metastatic colorectal cancer.

Daniel M. Halperin, MD, sheds light on the latest research in neuroendocrine tumors.

Michael Overman, MD, highlights data from pivotal trials presented at the 2019 Gastrointestinal Cancers Symposium and discusses where research efforts should be focused to improve the treatment of patients with colorectal cancer.

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses recognizing tumor sidedness in the treatment of patients with metastatic colorectal cancer.

Sumit K. Subudhi, MD, PhD, discusses the promise of the combination of nivolumab and ipilimumab in patients with metastatic castration-resistant prostate cancer and the challenges that lie ahead with this treatment approach.

Hussein A. Tawbi, MD, PhD, associate professor, The University of Texas MD Anderson Cancer Center, discusses unmet needs in melanoma.

Srdan Verstovsek, MD, PhD, director of the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms at The University of Texas MD Anderson Cancer Center, discusses the toxicity profile of ruxolitinib in the treatment of patients with myeloproliferative neoplasms.

Cathy Eng, MD, FACP, discusses the current treatment options available for patients with metastatic colorectal cancer and highlights recent data in the space.

Srdan Verstovsek, MD, PhD, discusses the use of interferon in rare blood diseases.

Sumit K. Subudhi, MD, PhD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the rationale for the CheckMate-650 study in the treatment of patients with metastatic castration-resistant prostate cancer.

Douglas A. Nelson, MD, Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses novel combination therapies in colorectal cancer (CRC).

Jonathan Mizrahi, MD, hematology/oncology fellow, The University of Texas MD Anderson Cancer Center, discusses bevacizumab (Avastin) as a chemoprotectant in colorectal cancer (CRC).

Michael Wang, MD, a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses updated data with single-agent acalabrutinib in mantle cell lymphoma.

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses the treatment landscape in newly diagnosed metastatic colorectal cancer (mCRC).

Srdan Verstovsek, MD, PhD, director of the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms at The University of Texas MD Anderson Cancer Center, discusses the benefit of ruxolitinib in polycythemia vera.

The Lung Cancer Master Protocol, known as the first precision medicine trial in lung cancer supported by the National Cancer Institute, has expanded to include patients with all types of non–small cell lung cancers.

Michael J. Overman, MD, highlights new combination agents under investigation for the treatment of patients with GI cancers—specifically CRC—and challenges that still need to be addressed.

Michael A. Choti, MD, highlights ongoing developments in the field of pancreatic cancer.

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the rarity of fusions in patients with colorectal cancer (CRC).

Michael A. Choti, MD, chief of surgery, Banner MD Anderson Cancer Center, discusses the role of immunotherapy in the treatment of patients with pancreatic cancer.

Michael Wang, MD, a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses next steps for research with acalabrutinib in mantle cell lymphoma.